Cerebral Assessment Systems is a company with a shared philosophy and goal in mind: to make the assessment of cognitive function as routine as having one’s blood pressure checked.
Dr. Charles J. Duffy, M.D., Ph.D., is Cerebral Assessment Systems’ founder, and the inventor of the company’s chief product: the Cognivue cerebral assessment solution. Cognivue has a rich history behind it, as it is based on years of neurophysiology and psychophysical research focusing on early detection of late-life cognitive decline (LLCD) and dementia.
The research most relevant to CAS technology began at the National Eye Institute at the National Institutes of Health, and extended for more than 23 years at the University of Rochester Medical Center. The goal of the research was to better understand the distinct neural mechanisms of impairment in aging, including dementia and Alzheimer’s disease. At CAS, Dr. Duffy conducted a series of studies, with the final, pivotal study leading to the FDA clearance of Cognivue.
The Cognivue cognitive assessment system is the first-of-its-kind, computer-based solution to assess, measure, and monitor brain health to detect early signs of dementia in patients over the age of 55.
As the world learns more and more about the devastating human and economic effects of the worldwide epidemic of dementia, the Cognivue cognitive assessment system is meant to be a solution through the automated measuring and monitoring of brain health, thereby detecting the early signs of dementia.
The single, unifying mission of CAS is to bring cognitive care to primary care—and in so doing, make routine assessment and monitoring of brain health and detection of the early signs of dementia more accessible, available, and accurate for physicians and patients worldwide.
Cognivue enables brain health testing, which can detect early signs of dementia by providing accessible testing across time and location, immediate results and a single, quantitative brain health score. Use of the test also works in tandem with effective treatment and better outcomes, such as treating reversible dementia, managing co-morbidities, and avoiding complications, polypharmacy, and procedures.
The Cognivue cognitive psychophysical approach presents sensory signals to activate the perceptual and memory functions of various brain systems. Plus, it provides consistent rotatory response tasks to normalize the influence of top-down control signals.
This combination of approaches provides the opportunity to measure the perceptual and memory functional abilities across select, specific functional domains.
Cognivue manipulates the strength of the bottom-up signals to quantify domain-specific perceptual processing abilities. And superimposes an interfering mask stimuli of varying durations to quantify domain-specific memory processing abilities.
CAS’ creation of the Cognivue test comes at a time when a response to the growing global epidemic of LLCD is drastically needed. It’s technology, combined with a design scheme specifically aimed at use in primary care, provides the lowest possible cost and most widely accessible patient-care setting available.
For more on Cerebral Assessment Systems, visit the company’s website.